Dr. Barbara Geladakis is a physician scientist, inventor and entrepreneur working at the nexus of clinical research, laboratory science and commercial innovation in reproductive immunology and fertility care. With more than a decade of clinical practice, she is a recognized authority on immune mediated reproductive failure, including recurrent miscarriage and implantation failure of immune etiology. In 2018 she founded RODI FERTILITY in New York and expanded its offices in Greece and Cyprus to translate scientific insight into patient centered diagnostics and therapies. Leadership & impact As Founder & CEO, Dr. Geladakis leads RODI’s R&D, clinical validation and international commercialization across Europe and the Middle East, delivering first in class solutions grounded in rigorous evidence. RODI Fertility has been recognized by multiple startup organisations as a trailblazing success story for its scientific rigor, market traction and social impact. A prolific inventor, Dr. Geladakis holds 54 granted patents worldwide with further PCT filings pending, reflecting a sustained pipeline of diagnostics and therapeutic innovations. She is author of several clinical studies and her work is cited in Immunobiology of Recurrent Miscarriage (H. Carp, ed.). She received the scientific award at the Panhellenic Congress of Autoimmune Diseases for best clinical study (2019). A regular invited speaker at major scientific congresses (ESRI, ESHRE, ISRIs world congress, EFI), Dr. Geladakis also presents at high level fora including the World Economic Forum and other entrepreneurship events. She engages actively in policy and investor dialogues on health innovation, access and commercialization. She is a member of the Hellenic Society of Immunology (HSI); European Society for Reproductive Immunology (ESRI) and a Polyglot speaking fluently in Greek, English, German, Serbian and Italian. She is committed to translating rigorous science into clinical solutions that restore hope to couples facing immune related fertility challenges, Dr. Geladakis aims to position RODI Fertility as a global leader in immune focused fertility diagnostics and adjunctive therapies through robust evidence, strategic IP protection and international partnerships.